252 related articles for article (PubMed ID: 27527815)
1. Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): A population-based assessment.
Guerra FM; Rosella LC; Dunn S; Wilson SE; Chen C; Deeks SL
Vaccine; 2016 Sep; 34(39):4678-4683. PubMed ID: 27527815
[TBL] [Abstract][Full Text] [Related]
2. Health service utilisation for anogenital warts in Ontario, Canada prior to the human papillomavirus (HPV) vaccine programme introduction: a retrospective longitudinal population-based study.
Guerra FM; Rosella LC; Dunn S; Wilson SE; Chen C; Deeks SL
BMJ Open; 2016 Mar; 6(3):e009914. PubMed ID: 26966057
[TBL] [Abstract][Full Text] [Related]
3. The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada.
Steben M; Ouhoummane N; Rodier C; Sinyavskaya L; Brassard P
J Med Virol; 2018 Mar; 90(3):592-598. PubMed ID: 28980715
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data.
Thöne K; Horn J; Mikolajczyk R
BMC Infect Dis; 2017 Aug; 17(1):564. PubMed ID: 28806926
[TBL] [Abstract][Full Text] [Related]
5. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts.
Smith LM; Strumpf EC; Kaufman JS; Lofters A; Schwandt M; Lévesque LE
Pediatrics; 2015 May; 135(5):e1131-40. PubMed ID: 25917991
[TBL] [Abstract][Full Text] [Related]
6. Incidence of anogenital warts after the introduction of the quadrivalent HPV vaccine program in Manitoba, Canada.
Righolt CH; Willows K; Kliewer EV; Mahmud SM
PLoS One; 2022; 17(4):e0267646. PubMed ID: 35472093
[TBL] [Abstract][Full Text] [Related]
7. Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006-2014: The impact of human papillomavirus vaccination.
Shing JZ; Hull PC; Zhu Y; Gargano JW; Markowitz LE; Cleveland AA; Pemmaraju M; Park IU; Whitney E; Mitchel EF; Griffin MR
Papillomavirus Res; 2019 Jun; 7():141-149. PubMed ID: 30980966
[TBL] [Abstract][Full Text] [Related]
8. Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017.
Checchi M; Mesher D; Mohammed H; Soldan K
Sex Transm Infect; 2019 Aug; 95(5):368-373. PubMed ID: 30723186
[TBL] [Abstract][Full Text] [Related]
9. Temporal Trends in the Incidence of Anogenital Warts: Impact of Human Papillomavirus Vaccination.
Naleway AL; Crane B; Smith N; Francisco M; Weinmann S; Markowitz LE
Sex Transm Dis; 2020 Mar; 47(3):179-186. PubMed ID: 31880738
[TBL] [Abstract][Full Text] [Related]
10. Early Evidence of the Effectiveness of the Human Papillomavirus Vaccination Program Against Anogenital Warts in Manitoba, Canada: A Registry Cohort Study.
Willows K; Bozat-Emre S; Righolt CH; Kliewer EV; Mahmud SM
Sex Transm Dis; 2018 Apr; 45(4):254-259. PubMed ID: 29465699
[TBL] [Abstract][Full Text] [Related]
11. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
Nygård S; Nygård M; Orumaa M; Hansen BT
Vaccine; 2023 Aug; 41(37):5469-5476. PubMed ID: 37516572
[TBL] [Abstract][Full Text] [Related]
12. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
[TBL] [Abstract][Full Text] [Related]
13. Incidence of anogenital warts: epidemiological risk factors and real-life impact of human papillomavirus vaccination.
Tyros G; Mastraftsi S; Gregoriou S; Nicolaidou E
Int J STD AIDS; 2021 Jan; 32(1):4-13. PubMed ID: 33167803
[TBL] [Abstract][Full Text] [Related]
14. Partial Protective Effect of Bivalent Human Papillomavirus 16/18 Vaccination Against Anogenital Warts in a Large Cohort of Dutch Primary Care Patients.
Woestenberg PJ; Guevara Morel AE; Bogaards JA; Hooiveld M; Schurink-van 't Klooster TM; Hoebe CJPA; van der Sande MAB; van Benthem BHB
Clin Infect Dis; 2021 Jul; 73(2):291-297. PubMed ID: 32421775
[TBL] [Abstract][Full Text] [Related]
15. Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain: Population-based analysis of anogenital warts in men and women.
Brotons M; Monfil L; Roura E; Duarte-Salles T; Casabona J; Urbiztondo L; Cabezas C; Bosch FX; de Sanjosé S; Bruni L
Prev Med; 2020 Sep; 138():106166. PubMed ID: 32565118
[TBL] [Abstract][Full Text] [Related]
16. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women--an ecological study.
Sandø N; Kofoed K; Zachariae C; Fouchard J
Acta Derm Venereol; 2014 May; 94(3):288-92. PubMed ID: 24150529
[TBL] [Abstract][Full Text] [Related]
17. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure.
Lurie S; Mizrachi Y; Chodick G; Katz R; Schejter E
Gynecol Oncol; 2017 Aug; 146(2):299-304. PubMed ID: 28602548
[TBL] [Abstract][Full Text] [Related]
18. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services.
Oliphant J; Perkins N
N Z Med J; 2011 Jul; 124(1339):51-8. PubMed ID: 21952330
[TBL] [Abstract][Full Text] [Related]
19. Increasing incidence of anogenital warts with an urban-rural divide among males in Manitoba, Canada, 1990-2011.
Thompson LH; Nugent Z; Blanchard JF; Ens C; Yu BN
BMC Public Health; 2016 Mar; 16():219. PubMed ID: 26939696
[TBL] [Abstract][Full Text] [Related]
20. Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014.
Flagg EW; Torrone EA
Am J Public Health; 2018 Jan; 108(1):112-119. PubMed ID: 29161070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
